December 6, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Nivalis Therapeutics Inc (NASDAQ:NVLS) shares over potential securities laws violations by Nivalis Therapeutics Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Nivalis Therapeutics Inc (NASDAQ:NVLS) concerning whether a series of statements by Nivalis Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 28, 2016, Nivalis Therapeutics Inc announced that its Phase 2 Trial of Cavosonstat failed to meet its primary endpoint of demonstrating a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at 12 weeks, in comparison to placebo.

Shares of Nivalis Therapeutics Inc (NASDAQ:NVLS) declined on December 5, 2016, to as low as $2.02 per share.